Nevertheless, although previous studies have shown the effect of SGLT2 inhibitors on diabetic patients at a high risk for cardiovascular disease, their effect on T2DM patients with stabilized AMI remains unknown. This evidence concerns the gene SLC5A2 and cardiovascular disorder.